NoctuRNA Therapeutics develops circular RNA-based therapies that target structural RNA elements critical to the progression of various diseases, including infectious and neuromuscular disorders. Their approach combines these therapies with advanced delivery techniques to address currently incurable conditions.
Funding
$711.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including infectious and neuromuscular disorders, progress due to structural RNA elements. Addressing these elements with traditional methods is challenging, leaving many conditions incurable.
Solution
NoctuRNA Therapeutics develops circular RNA-based therapies specifically designed to target the structural RNA elements that drive disease progression. By combining these targeted therapies with advanced delivery techniques, NoctuRNA aims to effectively address and treat diseases that are currently considered intractable. This approach offers a novel way to intervene in disease pathways by directly targeting the root cause at the RNA level.
Target Audience
The primary target audience includes patients suffering from infectious and neuromuscular disorders, as well as researchers and clinicians seeking novel therapeutic approaches for these conditions.
Features
- Circular RNA-based therapeutics targeting structural RNA elements.
- Advanced delivery techniques for effective therapeutic delivery.
- Applicability to a wide range of pathologies, including infectious diseases and neuromuscular disorders.